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GENERAL INTRODUCTION 
 
- Pompe disease 
Pompe disease (PD, glycogen storage disease type II) is a metabolic myopathy caused 
by mutations of the GAA gene and by functional deficiency of the acid alpha-
glucosidase (GAA, acid maltase), a glycoside hydrolase involved in the lysosomal 
breakdown of glycogen [1]. The lack of functional GAA results in extensive glycogen 
storage in multiple tissues and massive accumulation of autophagic vesicles and 
autophagic debris in muscles [2]. 
The GAA gene, localized in 17q25.2-q25.3, consists of 20 exons spread over 28 kb of 
genomic sequence and encodes a protein of 952 amino acids with a predicted 
molecular mass of 110 kDa [3]. The 110 kDa GAA protein synthesized in the 
endoplasmic reticulum is a precursor polypeptide, which undergoes N-glycan 
processing in the Golgi apparatus, and is proteolytically processed in the lysosomes into 
active isoforms of 76 and 70 kDa, through an intermediate molecular form of 95 kDa [4]. 
In lysosome, the mature enzyme hydrolyzes the α-1,4 and 1,6-glycosidic bonds of 
glycogen, releasing glucose units that are then transported across the lysosomal 
membrane by a specific carrier [5]. 
Being GAA deficiency ubiquitous in PD, glycogen storage occurs in almost every tissue 
and cell type. However, disease manifestations are predominantly related to muscle 
involvement and heart and skeletal muscle are the major sites of pathology.  
Muscle pathology has been extensively studied by several approaches, including 
immuno-histochemical procedures (with a wide range of cellular markers), and electron 
microscopy (Fig. 1). Muscle fibers show extensive vacuolization, with vacuoles 
containing glycogen particles, cytoplasmic debris, electron dense bodies, and 
multilamellar structures. Glycogen deposition may be seen also outside the vacuoles. 
2 
 
Particular interest has been recently paid to the presence of central accumulation of 
autophagic lipofuscin-like material [6]. In addition to these typical markers of PD 
pathology, other morphological changes have been described, such as the proliferation 
of the Golgi apparatus and abnormal caveolin expression [7, 8]. Despite the large 
number of studies, there are issues that remain unclear. 
 
Fig.1 (A) Electron microscopy: glycogen accumulation in PD muscle fibers. (B) PAS staining in PD muscle that shows glycogen 
accumulation. (C) PD muscle fibers show extensive vacuolization, with vacuoles containing glycogen particles and cytoplasmic 
debris. 
 
So far more than 500 different GAA gene variations have been identified (The Human 
Gene Mutation Database, HGMD) and the type of mutation correlates in most cases 
with the residual enzyme activity. GAA activity may range from complete deficiency 
(<1%) in the severe forms, to partial (up to 30%) deficiency in milder forms. PD is often 
due to missense mutations in GAA gene that causes the synthesis of a misfolded 
enzyme protein.  
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Traditionally, PD patients have been classified into distinct categories, including an early 
onset “classical” form, early onset intermediate phenotypes, and the attenuated late 
onset juvenile and adult forms. 
The “classic” infantile-onset form represents the severe end of this spectrum with a 
clearly defined phenotype, characterized by severe hypertrophic cardiomyopathy typical 
ECG pattern, generalized hypotonia and a rapidly progressive course. When untreated, 
classic infantile PD patients die by the end of the first year [9, 10]. 
In the late-onset, slowly progressive juvenile and adult-onset forms symptoms related to 
skeletal muscle dysfunction, resulting in both mobility and respiratory problems, are the 
primary manifestations [11]. The first symptoms usually start between the second and 
fourth decade and are in most instances related to impaired mobility and limb-girdle 
weakness. The age at onset, the rate of disease progression and the sequence of 
respiratory and skeletal muscle involvement vary substantially among different patients. 
The clinical variability makes diagnosis difficult and in several cases the final diagnosis 
is made many years after the start of symptoms. 
Intermediate phenotypes (early onset without cardiomyopathy, childhood-onset) have 
also been described and characterized. 
 
- Therapy for Pompe disease: Enzyme replacement therapy 
The only approved treatment for PD is Enzyme replacement therapy (ERT) with 
recombinant human GAA (rhGAA). ERT is based on the concept that recombinant 
lysosomal hydrolases, in most cases enzyme precursors manufactured on large scale in 
eukaryotic cells systems (chinese hamster ovary cells), can be administered periodically 
to patients by an intravenous route. The enzymes are internalized by patients’ cells and 
tissues through the mannose or mannose-6-phosphate receptor pathways and are 
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ultimately delivered to lysosomes, where they are activated and replace the function of 
the defective hydrolases. The presence of mannose-6-phosphate ligands in the enzyme 
molecules and the integrity of the mannose-6-phosphate receptor pathway in the target 
cells and tissues are therefore crucial for the efficacy of this therapeutic approach. 
In PD ERT showed remarkable success in reversing cardiac involvement in infantile-
onset patient [12, 13, 14, 15, 16, 17]. Cardiac manifestations in most cases responded 
quickly and strikingly to ERT, with rapid regression of ventricular hypertrophy and near 
normalization of ventricular function.  
However, limitations of ERT are becoming evident. First, not all patients respond 
equally well to treatment. Second, it is now clear that skeletal muscle (one of the major 
sites of disease and an important target of therapy) is more refractory to treatment than 
other tissues. Why this happens remains to be fully elucidated. It has been proposed 
that several factors concur in reducing the effectiveness of ERT in skeletal muscle. One 
of these factors is the preferential uptake of rhGAA by liver and the insufficient targeting 
of the enzyme to skeletal muscle [18]. The large mass of skeletal muscle and the 
relative deficiency of the mannose-6-phosphate receptors in muscle cells [19] also 
contribute to the poor correction of GAA activity.  
Additional information derived from the studies performed in cultured fibroblasts from 
PD patients with different clinical forms showing abnormal cellular distribution of the CI-
MPR [8]. These studies showed that mislocalization of the CI-MPR (the cation-
independent mannose-6-phosphate receptor) resulted in less efficient internalization 
and lysosomal trafficking of rhGAA, mediated by this receptor. The degree of cellular 
abnormalities varied among the different cell lines and was correlated with the reduced 
uptake of rhGAA, indicating a possible mechanism for the variable response to ERT 
observed in different patients. 
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- The pathophysiology of PD 
The role of secondary cellular events triggered by glycogen storage is now becoming a 
major field of investigation in PD. The spectrum of such abnormalities covers a wide 
range of events, including modulation of receptor responses and signal transduction 
cascades, activation of inflammatory responses, impaired intracellular trafficking of 
vesicles, membranes and membrane-bound proteins, impairment of autophagy, and 
others [20, 21]. 
Specifically, the derangement of autophagy is the most extensively studied and 
accurately characterized of these cellular abnormalities. Autophagy is a dynamic 
process involving the rearrangement of subcellular membranes to sequester cytoplasm 
and organelles in autophagic vesicles for delivery to lysosomes or vacuoles where the 
sequestered cargo is degraded and recycled [21]. For autophagy to accomplish its 
biological function (i.e. the turn-over of macromolecules and organelles), autophagic 
vesicles must fuse to lysosomes to form autophagolysosomes. When autophagy is 
blocked protein turn-over is impaired, causing the accumulation of ubiquitinated protein 
aggregates. In PD a number of studies demonstrated the massive accumulation of 
autophagic debris in the core of muscle fibers, decreased vesicular trafficking in cells, 
and an acidification defect in a subset of late endosomes/lysosomes [22, 23]. Why PD 
cells show an autophagic “build-up” and how these abnormalities contribute to muscle 
cell damage, however, remain to be fully elucidated. It is reasonable to speculate that 
further studies on the molecular mechanisms and cellular events elicited by glycogen 
storage will identify additional factors (i.e. oxidative stress, activation of genes 
responsible for the apoptotic cascade, etc) that may play a role in PD pathophysiology. 
In addition to the abnormalities of autophagy, studies in PD fibroblasts demonstrated 
aberrant Golgi and trans-Golgi network morphology [8]. The abnormalities of the Golgi 
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apparatus were associated with changes in the distribution of CI-MPR, a membrane-
bound protein mostly localized in these organelles. CI-MPR is sequestered in relatively 
inert vesicles deriving from the fusion of autophagosomes with substrate-engulfed 
lysosomes. An important consequence of the sequestration of CI-MPR in these 
organelles, is a depletion of functionally available CI-MPR at the plasma membrane. It 
is becoming clear that secondary cellular abnormalities may negatively affect the 
efficacy of the therapies currently available, thus providing clues to clarify the reasons 
for the variable response of different patients and tissues to therapies. 
 
AIM OF THE THESIS 
While the genetics and the biochemistry of PD are well characterized, the molecular 
bases underlying the secondary cellular abnormalities are not clear. Several studies 
have been focused on abnormalities in the expression of the genes implicated in the 
control of housekeeping cellular functions. The general aim of my thesis is to improve 
the knowledge of PD pathophysiology and characterize pathways identifying novel 
targets for the treatment of PD, that may translate into improved efficacy of the ERT. 
As I just mentioned, PD is characterized  by different abnormalities in autophagy, in 
Golgi apparatus, in the CI-MPR distribution or in intracellular vesicular trafficking, so we 
thought it could be interesting to investigate also about the proteins interacting with 
GAA in normal condition and in PD. Secondary, we investigated about the other 
pathway that may be associated with autophagy abnormalities in a relationship of 
cause and effect. Among all molecular mechanisms, recently oxidative stress has been 
shown having a key role in autophagy regulation [24, 25]. In line with this evidence, the 
second aim of this work is to characterize the presence of ox-stress in PD and to 
investigate the possible role of ox-stress in ERT improvement. 
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Moreover, we have explored the potential of microRNAs (miRNAs) as new tool for 
understanding of the diseases pathophysiology and as new potential biomarkers to 
follow disease diagnosis, progression and follow up of patients. So far, there are 
several examples of alterations in the levels of circulating miRNAs associated with a 
disease condition. 
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Acid-alpha glucosidase interactions and pathophysiology  
of Pompe Disease. 
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INTRODUCTION AND OBJECTIVES 
It is now clear that in PD, as well as in the others lysosomal storage diseases (LSDs), 
substrate storage leads to several alterations in cellular functions and pathways. 
Multiple abnormalities of cell morphology, including lysosomal and cytoplasmic 
glycogen accumulation, the presence of multivesicular bodies, the disruption of the 
normal structure of the Golgi apparatus, were observed in fibroblasts cultured from PD 
patients with the different clinical forms of the disease both by electron microscopy 
analysis and by immunofluorescence studies [1]. The abnormalities of the Golgi 
apparatus were associated with changes in the distribution of CI-MPR, a membrane-
bound protein mostly localized in these organelles. CI-MPR traffics within cells following 
different itineraries, such as the lysosomal enzyme biosynthetic pathway and the 
endosomal pathway; along these routes transit through the trans-Golgi network is an 
important stage. The finding of increased co-localization of the CI-MPR with LC3, a 
marker of the autophagosomes and autophagolysosomes, supported the hypothesis of 
an impaired retrograde trafficking of the receptor from late endosomes to the trans-Golgi 
network, and indicated that, at least in part, CI-MPR is sequestered in relatively inert 
vesicles deriving from the fusion of autophagosomes with substrate-engulfed 
lysosomes. An important consequence of the sequestration of CI-MPR in these 
organelles, is a depletion of functionally available CI-MPR at the plasma membrane. It is 
becoming clear that secondary cellular abnormalities may negatively affect the efficacy 
of the therapies currently available, thus providing clues to clarify the reasons for the 
variable response of different patients and tissues to therapies. Correction of secondary 
cellular abnormalities may represent an additional and novel target of therapy. 
Moreover, impaired intracellular trafficking of vesicles and altered membranes and 
membrane-bound proteins have been described but there are no evidence about the 
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mechanisms underlying these events. Aberrant membrane cholesterol and SNARE 
levels in LSDs cells may determine lysosomal and endocytic traffic dysfunctions [2], but 
also some aberrant protein interactions could constitute additional factors that contribute 
to the occurrence of abnormalities of vesicle trafficking and CI-MPR distribution in PD. 
In view of these considerations, we have analyzed protein interactions in PD. 
This project has been focused on the investigation of the intracellular pathways 
controlling GAA trafficking and how they change in the presence of amino acid 
mutations impairing GAA activity in order to understand the role of these interactions in 
PD pathophysiology.  
 
RESULTS 
Preliminary data obtained in collaboration with the Department of Chemical Sciences 
and CEINGE suggested that wild type GAA has several protein interactors (Table 1). In 
particular, Immunoprecipitation (IP) experiments and analysis of Nanoliquid 
Chromatography-Tandem Mass Spectrometry (nanoLC-MS/MS) on protein extracts 
from control fibroblasts showed a list of wild type GAA protein interactors and, 
surprisingly, most of them belong to the cytoskeleton. Recently, it has been shown that 
some cytoskeleton-associated proteins (i.e. myosin 1G (MYO1G), myosin heavy chain 1 
(MYH1) and tropomyosin 2 (TPM2) ) are essential for lysosomal stability in human 
breast cancer cells and their inactivation by the use of specific siRNAs induced several 
changes in the endo-lysosomal compartment, such as an increased lysosomal volume, 
an altered lysosomal localization, and a reduced autophagic flux [3]. Therefore this 
results seems to be very interesting. So, we selected some of these proteins to confirm 
the preliminary results obtained with nanoLC-MS/MS.  
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Table. 1 This table describe possible wild type GAA protein interactors obtained by Immunoprecipitation (IP) experiments and 
nanoLC-MS/MS analysis on protein extract from control fibroblasts. This data have been obtained in collaboration with the 
Department of Chemical Sciences and CEINGE. 
 
We have further confirmed these interactions by immunoprecipitation studies and 
western blot analysis. 
 
Myosin 1C 
Class 1 myosins are particularly interesting, since they can simultaneously associate 
with membranes and actin filaments [4], thereby regulating membrane– cytoskeleton 
adhesion [5]. Accordingly, they participate in endocytosis, exocytosis, and regulation of 
tension between the cytoskeleton and the plasma membrane [6].  
It has been shown that a myosin I family member (MYO1C) is required for optimal 
insulin-stimulated translocation of intracellular membranes containing GLUT4 glucose 
transporters to the plasma membrane [7]. In light of this finding, and of the fact that 
MYO1C is one of the GAA interacting protein found by nanoLC-MS/MS analysis, we 
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decided to validate the interaction between MYO1C and GAA by co-
immunoprecipitation and western blot analysis. 
Total extract from control fibroblasts were incubated with magnetic beads linked to anti 
GAA antibody that retains GAA and other proteins interacting with GAA. Complexes 
were eluted from beads and analyzed by western blot analysis revealing for MYO1C 
(Fig. 2). 
 
 
 
 
 
 
Fig. 2 Picture representing the co-immunoprecipitation analysis steps. 
 
Total extract were also immunoprecipitated with Myo 1C antibody and revealed for GAA 
by western blotting. As negative control, total extracts were incubated in absence of 
antibodies. The interaction between these two proteins was confirmed in both the 
experiments (Fig. 3).  
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Fig. 3 Western blot analysis of GAA-MYO1Cco-immunoprecipitations. The left panel shows the detection of MYO1C on GAA 
immunoprecipitates obtained from control fibroblasts. The right panel shows the detection of GAA in MYO1C immunoprecipitates. 
The negative controls (third lanes) represents the cell lysates incubated without antibody. The results confirm the interaction 
between the two proteins. 
 
Tropomyosin 3  
Tropomyosin was primarily regarded as a muscle protein that regulates the interaction 
of actin-containing thin ﬁlaments with myosin ﬁlaments to allow contraction [8]. Multiple 
tropomyosin isoforms are also expressed in non-muscle cells where tropomyosins 
participate in a number of cytoskeleton-mediated cellular processes [9, 10]. A widely 
accepted function of tropomyosins in non-muscle cells is to stabilize actin ﬁlaments 
mechanically, and possibly to protect against the action of ﬁlament-destabilizing 
proteins and disassembling drugs [11]. 
To validate the interaction between GAA and tropomyosin 3 (TPM3) we performed co-
immunoprecipitation and western blot analysis on total extract from control fibroblasts in 
the same conditions used for GAA-MYO1C co-immunoprecipitation analysis (Fig. 4). 
The results of these experiments confirm the interaction between GAA and TPM3. 
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Fig. 4 Western blot analysis of GAA-TPM 3 co-immunoprecipitations. The first panel shows the detection of TPM3 on GAA 
immunoprecipitates from control fibroblasts, the opposite in the second panel. Also in this case the interaction between GAA and 
TPM3 was confirmed.  
 
Myosin VI 
Myosin VI (MYO6) is a 140 kDa ATP-sensitive actin binding protein that consists of an 
N-terminal highly conserved motor domain that can bind ATP and filamentous actin 
(Fig. 5). It is followed by a neck region and a C-terminal tail domain. Between the motor 
domain and neck region there is an addictional unique 53 amino acid insert which has 
been predicted to be the “reverse gear” that allows MYO6 to move towards the minus 
end of actin filaments [12]. Unexpectedly this insert has recently been shown to bind 
calmodulin [13] despite not containing a recognizable IQ-calmodulin binding motif. 
 
 
Fig. 5 Myosin VI is an ATP-sensitive actin binding protein that consists of an N-terminal highly conserved motor domain that can 
bind ATP and filamentous actin. It is followed by a neck region and a C-terminal tail domain. 
 
Myosin of class VI has the unique ability, unlike the rest of the myosin family, to 
translocate towards the pointed or minus end of actin filaments [14]. In mammalian 
cells, MYO6 has been shown to be involved in endocytosis, in membrane ruffling at the 
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leading edge of cells and in the maintenance of Golgi complex morphology and in 
secretion. Cellular localization studies have confirmed that MYO6 is present in clathrin-
coated and uncoated vesicles distributed throughout the cell, in membrane ruffles and in 
the Golgi complex network [15]. MYO6 involvement in endocytosis and in maintenance 
of Golgi morphology (both affected in PD cells morphology) and its possible interaction 
with wild type GAA suggest that this protein could have a role in GAA trafficking from 
ER to lysosome. 
To further investigate the interactions between GAA and MYO6, we also performed co-
immunoprecipitation studies on protein extract from control and mutant fibroblasts (Fig. 
6). We decided to select fibroblasts from a patient homozygous for the p.L552P GAA 
gene mutation. This mutation is associated with the synthesis of a misfolded protein and 
with a residual enzyme activity. MYO6 seems to interact with both wt and mutant GAA; 
in particular, in MYO6 immunoprecipitates different isoforms of the enzyme are 
represented (a 95 kDA precursor isoform and the two 76 and 70 kDa mature forms). 
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Fig.6 Western blot analysis of GAA-MYO6 co-immunoprecipitations. A) The first panel shows the detection of MYO6 on GAA 
immunoprecipitates obtained from control fibroblasts.The second one shows the detection of GAA on MYO6  
immunoprecipitates.The results confirm the interaction between GAA and MYO6.B) The first panel shows the detection of MYO6 on 
GAA immunoprecipitates from L552P fibroblasts, the opposite in the second panel. Also in this case the interaction between GAA 
and MYO6 was confirmed. MYO6 shows interaction with both wt and mutant GAA. 
 
Gelsolin 
Gelsolin (GSN) is the most potent actin filament severing protein identified to date. 
Severing is the weakening of enough non-covalent bonds between actin molecules 
within a filament to break the filamentin two [16]. GSN is composed of six domains, 
designated (from the N-terminus) as G1–G6 (Fig. 7). Each domain contains Ca2+-
binding site. The helical tail is in close contact with the actin binding helix of G2 and may 
act as a latch to inhibit actin binding. Recent studies show that residues in the Ca2+-
binding sites of G2 and G6 are involved in regulating GSN structure, including 
stabilizing the Ca2+-free state, promoting transitions through intermediate states and 
stabilizing the Ca2+-bound state. Ca2+-binding by G2 is critical in the activation and 
stabilization of GSN [17]. The disulﬁde bond in G2 is involved in Ca2+ activation of GSN. 
The most extensively examined roles of GSN relate to its ability to sever, cap, uncap, 
A 
B 
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and nucleate actin ﬁlaments. GSN can bind to actin monomers and ﬁlaments, and is 
regulated by pH, phosphoinositides, lysophosphatidic acid, and high 
micromolarconcentrations of Ca2+ [18]. The GSN capability to interact with actin and to 
regulate its polymerization, associated with its possible interaction with GAA, led us to 
focus on this protein. In fact, studies in GAA knock-out mice showed that the presence 
of glycogen-filled lysosomes in muscle fibers interferes with the architecture and 
function of the contractile apparatus with a mechanical effect [19]. X-ray diffraction 
studies showed that, although the content of contractile proteins was equivalent, actin 
and myosin filaments were disordered in the PD muscle, and that actin and myosin 
interactions were disrupted. Moreover, in 2009 Kelly et al showed that GSN alteration is 
involved in Familial amyloidosis of Finnish type (FAF) or gelsolin amyloidosis. The 
D187N/Y mutation in plasma GSN enables an aberrant protein cleavage, generating a 
68-kDa fragment (C68) of GSN that is secreted. C68 can be further cleaved in the 
extracellular space to generate amyloidogenic fragments. Deposition occurs in skeletal 
and cardiac muscle, leading to cardiomyopathy and muscle weakness [20], that are also 
the clinical manifestations of PD. Furthermore, it has been shown that gelsolin can bind 
lipids and can become partially embedded in vesicle membranes at low pH values 
within the physiologically normal range [21] and that it can also control transport of the 
autonomous parvovirus Minute Virus of Mice from the nucleus to the cell periphery and 
release into the culture medium by (virus-modified)lysosomal/late endosomal vesicle 
transport [22]. All together these evidences led us to further investigate about the 
possible interaction between GSN and GAA and its functional role.   
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Fig. 7 Gelsolin has three different actin binding domains which are distributed within the six repeating segments (G1–G6) in the 
amino acid sequence of gelsolin. Monomer actin binding sites are present in segment G1 and G4–6, while the highest afﬁnity F-
actin binding site is located in G2–3. 
 
GSN exists in extracellular (secreted, pGSN) and intracellular (cytoplasmic, cGSN) 
forms, both of which are encoded by a single gene on chromosome 9 [23] in humans 
and on chromosome 2 in mouse, and are under the control of different promoters. The 
gene that codes both GSN isoforms is made up of at least 14 distinct exons which span 
a region of 70 kb. The arrangement of cGSN at the 5’-end is exon 1-intron-exon 2-
intron-exon 4. Collectively, exons 1 and 2, which are 13 kb apart in the gene, make up 
the unique 5’ untranslated region of cGSN. The 5’-end of the pGSN differs from the 
cGSN, as it is made up of exon3-intron-exon 4. Exon 3, which is found 2.3 kb upstream 
from exon 4, comprises a small region of untranslated sequence and codes for both the 
signal peptide and the ﬁrst 21 residues of the pGSN [24] (Fig. 8).  
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Fig. 8The human gene that codes both GSN isoforms is made up of at least 14 distinct exons which span a region of 70kb. The 
arrangement of cGSN at the 5’-end is exon 1-intron-exon 2-intron-exon 4. The 5’-end of the pGSN differs from the cGSN, as it is 
made up of exon3-intron-exon 4. 
 
Secreted GSN differs from intracellular gelsolin in having a signal peptide, a 25-residue 
amino-terminal extension and a disulphide bond between cysteines 188 and 201. 
Plasma GSN is larger than cytoplasmic GSN (Mr 93,000 versus 90,000, respectively) 
and is more positively charged. The two GSN share a common 29 amino acid sequence 
which lies at the NH-terminal end of cytoplasmic GSN and spans residues 26-55 of 
plasma GSN. Compared with cytoplasmic GSN, plasma GSN contains an additional 
peptide of 25 amino acids at its NH terminus.These two forms are structurally similar but 
not identical and after synthesis these proteins are processed independently, and have 
a distinct fate [24]. 
My study has been especially focused on the interaction between GAA and GSN. 
Western blot analysis of GAA-GSN co-immunoprecipitations showed that, unlike MYO6, 
GSN interacts with wild type GAA but there is no interaction with mutant GAA. 
Moreover, GSN appeared to interact mainly with the precursor (95 KDa) GAA isoform 
(Fig.9). 
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Fig. 9 Western blot analysis of GAA-GSN co-immunoprecipitations. A) The first panel shows the detection of GSN on GAA 
immunoprecipitates obtained from control fibroblasts.The second one shows the detection of GAA on GSN immunoprecipitates.The 
result confirm the interaction between GAA and GSN.B) The first panel shows the detection of GSN on GAA immunoprecipitates 
from L552P fibroblasts, the opposite in the second panel. GSN interacts with wild type GAA but there is no interaction with mutant 
GAA. Moreover, GSN appears to interact mainly with the precursor (95 KDa) GAA isoform. 
 
The interaction between GAA and GSN was not evident by immunofluorescence 
confocal microscopy experiment on control fibroblasts, because of the diffuse 
cytoplasmic distributionof GSN signal pattern.To circumvent this problem we performed 
a Proximity Ligation Assay (PLA) in control fibroblasts. This immunoassay employes 
species-specific secondary antibodies, called PLA probes, each with a unique short 
DNA strand attached to it. When the PLA probes are in close proximity (in case of 
protein interaction), the DNA strands can interact through a subsequent addition of two 
other circle-forming DNA oligonucleotides. After joining of the two added 
oligonucleotides by enzymatic ligation, they are amplified via rolling circle amplification 
using a polymerase, in presence of nucleotides and fluorescently labeled 
oligonucleotides. The resulting high concentration of fluorescence in each single-
molecule amplification product is easily visible as a distinct bright spot when viewed with 
a fluorescence microscope (Fig.10). As positive control we used the interaction 
B 
A 
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between Actin and GSN, in which we observed several red dots; as negative control we 
used GSN-LAMP2 staining that is associated with the absence of red dots. In GAA-
GSN staining we observed red dots in small but detectable amount and this result 
seems to confirm the interaction between GAA and GSN in control fibroblasts. 
 
 
Fig. 10 Proximity Ligation Assay on control fibroblasts. GSN-Actin staining is the positive control, GSN-LAMP2 the negative control. 
The results seem to confirm the interaction between GAA and GSN in control fibroblasts. 
 
Confocal microscopy immunofluorescence experiments in L552P fibroblasts showed 
that GSN signal seems to be more represented in L552P fibroblasts than in control 
fibroblasts (Fig. 11). We also performed western blot analysis in three control fibroblast 
and five PD fibroblast lines, obtained from patients with different phenotypes among 
them. In all patients there is a significant increase in the amount of GSN and the 
appearance of a 68 kDa GSN band. We have supposed that this band can be a 
cleavage product in PD fibroblasts but this suggestion have to be confirmed. 
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Fig. 11 A) Confocal microscopy analysis of Gelsolin distribution. The GSN signal seems to be more represented in L552P 
fibroblasts. B) Western Blot analysis of GSN isoforms. Quantitative analysis of the bands by ImageJ (right). Five PD fibroblast cell 
lines show a 68 kDa band in addition to the typical 80 kDa band. C) Quantitaive analysis of GSN isoforms.* p< 0,01 
 
Moreover, we have performed some analysis in a group of BALB/c GSN KO mice, in 
collaboration with Ronchi’s group at Bicocca University in Milan. Primary fibroblasts 
from WT and GSN KO mice were obtained from peritoneal biopsy. In order to evaluate 
the possible effect of GSN absence on GAA trafficking and maturation, we performed 
western blot analysis on fibroblasts lysates from WT and GSN KO mice. We used 
human control fibroblasts as positive control and PD human fibroblasts as negative 
control (Figure 12). Results showed the presenceof the mature and active form of GAA 
both in WT and GSN KO mice, but the pattern of the different isoforms of the enzyme 
seems to be different between GSN WT and KO. The reason of this result is not clear 
and further studies are necessary to clarify this point. 
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Fig. 12 A) Western blot analysis on fibroblasts lysates from WT and GSN KO mice. Control fibroblasts were used as positive control 
and PD human fibroblasts as negative control. B) Quantitative analysis of the different enzyme  isoforms.  
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METHODS 
Cell Culture 
Fibroblasts from control individuals and from PD patients were obtained from the cell 
repository at the Department of Traslational Medicine, Università degli Studi di Napoli 
Federico II.Fibroblasts were grown in DMEM medium supplemented with fetal bovine 
serum, L-glutamine and antibiotics. 
 
Immunoprecipitation and Western Blot 
Fibroblasts protein extracts were obtained by lysing cells with 2,5mM KCl, 150mM NaCl, 
50 mM Tris HCl pH 6.5, 0.1% Triton X-100 and protease inhibitors for 30 minutes at 
4°C. samples were centrifuged at 13000 rpm fot 30 minutes at 4°C. The supernatant 
constituted the protein extract. 1 milligrams of protein extract were immunoprecipitated 
with 20 μl of Dynabeads protein G (Life technologies AS, Oslo)  and 4 μl of antibody to 
GAA (rabbit polyclonal antibody provided by PRIMM) and 4 μg of antibody to GSN 
(Abcam) and MYO6 (LSBio) over night. Immunoprecipitated were immunoblotted and 
visualized with the chemiluminescent substrate ECL (GE Healthcare, Milan, Italy). 
 
Confocal microscopy analysis 
For immunoﬂuorescence (IF), fibroblasts were seeded on chamber slides, ﬁxed with 4% 
paraformaldehyde (PFA), treated with 0.1% Triton, incubated in blocking solution (0.5% 
BSA, 10% horse serum in PBS) for 20min, and then incubated overnight at 4°C with 
antibodies (the same used for immunoprecipitation, see above). Appropriate secondary 
ﬂuorescent antibodies (Alexa-Fluor, Invitrogen,Paisley, UK) were used. Slides were 
mounted using Vectashild medium with DAPI stain (Vector, Burlingame, CA, USA) and 
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examined on a ﬂuorescence Leica DM5000B microscope (Leica Microsystems Srl, 
Milan, Italy). 
 
GAA activity assay 
GAA activity was assayed by using the fluorogenic substrate 4-methylumbelliferyl-α-D-
glucopyranoside (Sigma-Aldrich). Briefly, 25 μg of protein were incubated with the 
fluorogenic substrate (2mmol/l) in 0,2 mol/l acetate buffer, pH 4.0, for 60 minutes in 
incubation mixtures of 20 μl. The reaction was stopped by adding 1 ml of glycine-
carbonate buffer, pH 10.7. Fluorescence was read at 365 nm (excitation) and 450 nm 
(emission) on a Turner Biosystem Modulus fluorometer.  
 
Proximity Ligation Assay (PLA) 
For PLA (OLINK Bioscience), fibroblasts were seeded on chamber slides, ﬁxed and 
permeabilized with Methanol for 10 min at -20°C and Acetone for 1 min at -20°C, 
incubated in blocking solution (1% BSA in PBS) for 15 min, and then incubated for 2 
hours with primary antibodies (the same used for immunoprecipitation, see above). 
Appropriate secondary antibodies were used. Fixed cells were incubated with PLA 
Probe for 1 hour at 37°C. Enzymatic ligation of the probes was performed by adding the 
ligation solution for 30 min at 37°C. Finally, the amplification solution was added and 
cells were incubated for 1 hour and 40 min at 37°C. Slides were mounted using 
Vectashild medium with DAPI stain (Vector, Burlingame, CA, USA) and examined on a 
ﬂuorescence Leica DM5000B microscope (Leica Microsystems Srl, Milan, Italy). 
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CONCLUSIONS 
PD is a metabolic myopathy caused by the deficiency of the lysosomal hydrolase GAA. 
Secondary abnormalities, such as altered Golgi and trans-Golgi network morphology 
and abnormal distribution of CI-MPR, play a major role in the occurrence of cell damage 
and muscular atrophy. The presence of these abnormalities led us to also investigate 
about the protein interacting with the GAA. Immunoprecipitation (IP) experiments and 
analysis of nanoLC-MS/MS on protein extract from human control fibroblasts showed a 
list of wild type GAA protein interactors and most of them belong to the cytoskeleton. In 
particular, we focused on some of this interactions. Co-immunoprecipitations and 
western blot analysis confirmed the GAA interaction with MYO1C, TPM3 and MYO6. In 
particular, we observed that MYO6 interact with both wt and mutant GAA.  
We focused on Gelsolin, a cytoskeleton protein that, when altered, is responsible of a 
Familial amyloidosis (FAF) that presents some clinical manifestations similar to PD, 
such as cardiomyopathy and muscle weakness [50]. Furthermore, there are evidences 
about its involvement in vescicle membrane structure at specific pH conditions [52].   
Western blot analysis of GAA-GSN co-immunoprecipitations showed that, unlike MYO6, 
GSN interacts with wild type GAA but there is no interaction with mutant GAA. 
Moreover, GSN appeared to interact mainly with the precursor (95 KDa) GAA isoform. 
This result suggested us that gelsolin can probably have a role in the first steps of GAA 
trafficking from ER to lysosome, where it is processed to the mature isoform, but so far 
its function is not clear. In order to confirm this interaction, we performed a Proximity 
Ligation Assay (PLA) in human control fibroblasts that revealed positive signals of GAA-
GSN interaction. 
GSN staining in human control and PD fibroblasts showed that GSN seems to be more 
abundant in mutant cells, in which there is the misfolded enzyme that is no properly 
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processed to lysosomes. These data were confirmed also by western blot analysis in 
PD and control fibroblasts. The same analysis showed the appearance of a 68 kDa 
GSN band in PD fibroblast, that seemed more abundant in intermediate patients, 
compared to severe. This band reminds to the 68 kDa cleaved fragment in FAF, so we 
have supposed that the 68 kDa band could be a cleavage product in PD cells. 
Obviously, this hypothesis needs to be further validated. 
The suggestion of a possible role of GSN in GAA maturation, has been supported by 
western blot analysis in fibroblasts from WT and GSN KO mice. Results showed the 
presence of the mature and active form of GAA both in WT and GSN KO mice, but the 
pattern of the different isoforms of the enzyme seemed to be different between GSN WT 
and KO. The reason of this result is not clear and further studies are necessary to clarify 
this point.  
All together this results lead us to further investigate about this novel interaction, whose 
meaning is still unclear. It is well known that in PD, such as in all LSD, there are 
impaired intracellular trafficking, abnormal distribution of CI-MPR and aberrant Golgi 
and trans-Golgi network morphology, but the molecular mechanisms underlying these 
events are still unknown. Our ongoing objectives is to further investigate about this 
interactions and to identify proteins and pathways involved in PD cellular abnormalities 
in order to improve our understanding of PD pathophysiology and to characterize new 
therapeutic targets.  
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Oxidative stress and PD 
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INTRODUCTION 
- Autophagic accumulation in Pompe disease 
The recent advancements in the knowledge of lysosomal biology and function have 
translated into a better understanding of the pathophysiology of LSDs. It is now clear 
that the clinical manifestations of these disorders are not only the direct effects of 
storage, but derive also from a cascade of secondary events that lead to dysfunction of 
several cellular processes and pathways. These processes include: secondary storage 
of substrates unrelated to the defective enzyme; abnormal composition of membranes, 
and their consequences on vesicle fusion and trafficking; impairment of autophagy; 
alteration of signaling pathways; oxidative stress; abnormalities of calcium homeostasis; 
and several others. Particular attention has been paid to the derangement of autophagy. 
In recent years it has been shown that a failure of productive autophagy in muscle 
tissue contributes strongly to disease pathology in PD patients [1]. Shea and Raben 
found an accumulation of autophagic vesicles in Type II-rich muscle fibers in the GAA 
knock-out mouse model and they showed that this build-up of autophagosomes disrupts 
the contractile apparatus in the muscle fibers [1]. Furthermore, the recombinant 
enzyme, given by ERT, uses the endocytic pathway to deliver the lysosomes, so it 
became clear that massive accumulation of autophagic material in muscle would 
interfere with the recombinant enzyme in ERT [2,3]. In fact, it has been shown that in 
muscle fibers from wild-type mice, rhGAA is efficiently targeted to lysosomes, while in 
GAA knock-out  muscle fibers, most of the endocytosed recombinant enzyme is 
accumulated in the central autophagic area and very little reached the lysosomes [1, 4]. 
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- Increased oxidative stress in Pompe disease 
It is reasonable to think that other pathways are dysregulated in PD and oxidative stress 
(ox-stress) appears to be interesting in this aspect. Increased ox-stress has been 
reported in different LSDs [5, 6]. In particular, Lim at al. have found multiple 
mitochondrial defects in mouse and human models of Pompe disease: a profound 
dysregulation of Ca2+ homeostasis, mitochondrial Ca2+ overload, an increase in reactive 
oxygen species, a decrease in mitochondrial membrane potential, an increase in 
caspase-independent apoptosis, as well as a decreased oxygen consumption and ATP 
production of mitochondria [7]. Moreover, they showed distended mitochondria with 
disarrayed cristae, often adjacent to the area of autophagic buildup, in muscle from 
GAA KO mice. These data are consistent with observations of changes in the 
morphology of mitochondria in muscle biopsies from Pompe patients. Cytosolic Ca2+ is 
significantly higher in KO myotubes and treatment with recombinant human GAA 
(rhGAA) results in a moderate decrease in Ca2+ levels [7]. 
 
- Autophagic pathway and oxidative stress 
Increased ox-stress is one of the potential factors implicated in induction of autophagy. 
Indeed, ox-stress has been recognized as an important activator of autophagy [8, 9]. 
Autophagy has been seen as an adaptive response to stress, which promotes survival. 
The regulatory pathways of autophagy acts in response to nutrients deprivation; in the 
extreme case of starvation, the breakdown of cellular components promotes cellular 
survival by maintaining cellular energy levels [9,10, 11]. 
The activation of autophagy in response to cellular needs is controlled by the 
mammalian target of rapamycin complex 1 (mTORC1) [12]. Active mTORC1 controls 
the activity of protein translation by direct phosphorylation of two key protein targets, 
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EIF4E-binding protein 1 (4E-BP1) and protein S6 kinase (p70S6K) [13]. Concomitantly, 
active mTORC1 prevents autophagy by phospho-inhibiting the UNC51-like kinase 1 
(ULK1) at Ser757 that interacts with two partners: the autophagy related gene 13 
(Atg13) and the FAK-family interacting protein of 200 kDa (FIP200). These three 
proteins form together the so-called ULK1 complex (Figure 1) [12, 14]. When mTORC1 
is inhibited, ULK1 is activated and is able to phosphorylate Atg13 and FIP200. This is 
the first step that leads to the autophagosome formation (Fig.1) [12, 14, 15]. 
 
 
Fig. 1 Cells coordinate energy and synthesis processes with the extracellular stimuli and amino acids and glucose availability. 
mTORC1is the unique molecular transducer of cellular needs. Once activated, mTORC1 activates protein synthesis by 
phosphorylating 4EBP1 and p70S6K, and concomitantly inhibits autophagy by phosphorylating ULK1 complex at the level of ULK1 
and Atg13 [8]. 
 
In the last years a growing amount of evidence argues for the correlation between 
oxidative stress and autophagy [8].  
Cells are always subjected to the effects of highly reactive oxidizing molecules thathave 
the ability to easily take electrons from cellular biomolecules and to trigger chain 
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reactions, leading to cell structure damage. The main classes of these molecules are 
reactive oxygen species (ROS) and reactive nitrogen species (RNS), endogenously 
produced at the highest concentration. It has been shown that ROS induce autophagy 
upon nutrient deprivation [16] and it is suggested by the evidence that antioxidant 
treatment prevents autophagy [17]. It has been proposed that the mitochondria 
represent the principal source of ROS required for autophagy induction [18, 19]; in fact, 
in lack of nutrients, the energetic stress increases ATP demand and causes 
mitochondrial overburden with an increasing ROS production. It could be possible that 
there is a factor which links mitochondria with the autophagic machinery. A hypothesis 
is that hexokinase II (HKII), the mitochondria-located enzyme responsible for the first 
step of glycolysis, binds to and inhibits mTORC1, loosing its ability to decrease ROS 
[20, 21, 22, 23]. 
AMPK could be another good candidate for a very fast induction of autophagy mediated 
by redox-sensitive proteins. Indeed, AMPK has been proposed to be activated by S-
glutathionylation (formation of a mixed disulphide with GSH) of its reactive cysteines 
located at the α- (Cys299 and Cys304) and β-subunits (Fig. 2) [24, 25]. The thiol redox 
homeostasis is crucial in autophagy and it is supported by the evidence that just the 
chemically oxidation of GSH is able to induce autophagy even in the absence of any 
autophagic stimulus [16]. This assumption is according to the fact that many proteins 
involved in autophagy activation are rich in Cys residues [16]. Along this line, also p62 
contains a zinc-finger motif (ZZ) rich in cysteine residues that that could be redox 
regulated.  
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Fig. 2 Importance of thiol redox homeostasis in autophagy . Ubiquitin-like systems Atg7-Atg3 and Atg7-Atg10, p62 and AMPK have 
cysteine residues that could be redox regulated [8] 
 
Autophagy and ox-stress have been shown to be interconnected in a more intimate and 
coordinated maner. Particularly, in 2010, it was discovered that p62 can activate the 
antioxidant transcription factor Nrf2 (nuclear factor erythroid 2-related factor 2) (Fig. 2). 
In absence of stress conditions, Kelch-like ECH- associated protein 1 (Keap1), that is 
an adapter protein of the Cul3-ubiquitin E3 ligase complex, degrade Nrf2 [26, 27]. In 
case of redox imbalance, p62, when phosphorylated at Ser351, binds to aggregates of 
ubiquitylated proteins and increases its affinity for Keap1 (Fig. 2), inducing Keap1 
degradation via autophagy [28, 29]. These events leave Nrf2 free to accumulate and 
translocate in the nucleus. Here, Nrf2 binds to the antioxidant-responsive elements 
(ARE) in the promoter regions of antioxidant and detoxifying genes [30], inducing their 
transcription (Fig. 2).  
These evidences show that ROS and RNS are the upstream modulators of autophagy, 
that is required for the cell to simultaneously overcome starvation and oxidative stress 
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conditions. Therefore, any dysfunction in this regard has been found to be involved in 
the onset of pathological states [31, 32, 33]. 
 
AIM OF THE PROJECT 
The general aim of this work is to improve the knowledge of PD pathophysiology. 
 
The first aim of this work was focused on the characterization of the presence of ox-
stress in PD mouse model and in patients’ cells.  
The second aim was focused on the study of the effects of pharmacological 
manipulation of the ox-stress pathway to improve muscle pathology and ERT efficacy. 
We used antioxidants and drugs that are already known to improve the oxidative status 
of cells, and evaluate their effects on disease pathology and clinical course of the 
disease. 
 
RESULTS 
- microRNA implicated in ox-stress or disregulated in PD mice. 
We analyzed miRNA expression profiles in tissues from PD mice with the aim to identify 
“disease-specific” miRNAs for PD (see 3rd part of this thesis). The analysis was 
performed in quadriceps, a tissue which is relevant for PD, on 3 months old mice by 
using a NextGeneration Sequencing (NGS) approach. The NGS analysis generated a 
list of differentially expressed miRNAs in a tissue which represents one of the primary 
target organs of PD. Interestingly, in the PD mouse muscle we found a deregulation of 
some miRNAs (Table 1). Some miRNA that are known to modulate target genes 
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involved in oxidative stress, autophagy and inflammation result to be differentially 
expressed in PD mouse muscle (Fig. 3). 
 
Fig. 3 MicroRNAs associated with oxidative stress that are dysregulated in PD mouse model. 
 
- Patients’ fibroblasts and GAA KO mice show increased ox-stress. 
Since free radicals and resulted products can be used as biomarkers of oxidative stress, 
we performed a Thiobarbituric Acid Reactive Substances (TBARS) to measure the 
amount of lipid peroxidation products using thiobarbituric acid as a reagent.We 
measured lipid peroxidation levels in homogenates from 3-months-old WT and KO PD 
mice (gastrocnemius, quadriceps, liver, heart, diaphram). The TBARS experiment has 
been performed also on fibroblasts isolated from patients. As shown in Fig.4, a 
significant increase was observed in the 4 muscles of PD mice compared to WT mice 
and in patients’ fibroblasts compared to control fibroblasts, suggesting the presence of 
oxidative stress in PD tissues and cells. The finding of minor increases in the liver 
suggested that the deregulation of the redox state is a typical feature of muscular 
tissues in PD, as expected in a metabolic myopathy such as PD [34]. 
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We also analyzed the intracellular ROS levels in 3 months PD mice and in fibroblasts 
isolated from patients and controls (Fig. 4A). DCFDA assay uses the cell permeant 
reagent 2’,7’ –dichlorofluorescin diacetate (DCFDA), a fluorogenic dye that measures 
hydroxyl, peroxyl and other reactive oxygen species (ROS) activity within the cell. We 
used cells and tissue homogenates to evaluate ROS levels. We found that in all the 
muscles analyzed, as well as in patients’ fibroblasts, a strong increase in ROS 
levelswas observed with respect to control samples. These data are in line with those 
obtained for lipid peroxidation. 
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Fig. 4 A )Lipid peroxidation and ROS production in 3 months PD mice and fibroblasts isolated from patients. Lipid peroxidation 
levels determined by TBARS assay in homogenates from different tissues in WT (white bars) and in PD samples (grey bars); 
intracellular ROS levels were determined by DCFDA assay. * p < 0.05, ** p<0.01. B) DCFDA staining in GAA WT e KO mice 
gastrocnemius. The results show a major amount of ROS in GAA KO mice than in GAA WT mice. Data shown are the means ± S.D. 
of three independent experiments.C) DTNB on PD and control fibroblasts. Results show a reduction of sulfhydryl groups, related to 
oxidative stress conditions, in PD fibroblasts compared to control fibroblasts. 
 
To validate these data we also performed a DCFDA staining in GAA WT and KO 
gastrocnemius (Fig. 4B) that confirms icreased ROS in GAA KO mice compared to WT 
mice.  
We used Ellman’s reagent (5,5'-dithiobis-2-nitrobenzoic acid or DTNB) which is a 
chemical used to quantify the sulfhydryl group of GSH in the cells. The thiol redox 
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homeostasis depends on the redox state of the cell. Results show a reduction of 
sulfhydryl groups, related to oxidative stress conditions, in PD fibroblasts compared to 
control fibroblasts (Fig. 4C). 
We next analyzed the expression of proteins involved in oxidative stress cascade by 
western blotting analysis in PD fibroblasts and muscles. MAPKs are a family of 
evolutionarily highly conserved enzymes that manage the response to growth 
stimulatory signals, such as insulin or epidermal growth factor (EGF), as well as 
adverse signals, such as cytotoxic and genotoxic substances. They include extracellular 
signal–regulated kinases (ERKs), stress-activated protein kinases, also known as c-jun 
N-terminal kinases (SAPK ⁄JNKs), and the p38-MAPKs (Fig. 5). Activation of these 
pathways is not unique to oxidative stress, as they are known to have central roles in 
regulating cellular responses to other stresses as well as regulating normal growth and 
metabolism. Indeed, in some situations the response to oxidants may involve 
overstimulation of normal ROS-regulated signalling pathways. In general, the heat 
shock response, ERK pathway exerts a pro-survival influence during oxidant injury, 
whereas activation p38 are more commonly linked to apoptosis [35]. Oxidants seem to 
activate the ERK, mimicking the actions of growth-factors [36, 37]. Oxidative stress 
might induce activation of the JNK and p38 kinase pathways by an additional 
mechanism. The redox regulatory protein thioredoxin (Trx) has been shown to activate 
an upstream factor of both JNK and p38, which is inhibited under normal conditions 
[38]. 
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Fig. 5 ROS can originate outside the cell, or may be generated intracellularly in response to external stimuli.  PI(3)K/Akt and MAPK 
pathways regulate transcription factors through phosphorylation. The consequences of the response vary widely, with the ultimate 
outcome being dependent on the balance between these stress-activated pathways. 
 
We analyzed the phosphorylation levels of p38 and ERK1/2 by western blots in human 
fibroblasts. This analysis confirmed that increased oxidative stress was present in PD 
patients (Fig. 6). 
 
Fig.6 Western blot analysis of P-ERK (1-2) in WT and PD fibroblasts. P-ERK (1-2)  seem to be more abundant in PD fibroblast 
compared to control. 
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Western blots analysis in gastrocnemii from WT and KO mice showed increased 
phosphorylation levels of p38 and ERK1/2 in PD mice than in control mice. This result 
was particularly evident in heart (Fig. 7). 
 
 
Fig. 7 Expression of genes involved in ox-stress in 3 months PD mice. Western blots of homogenates from quadriceps and hearts in 
wt and PD mice.* p < 0.05. 
 
We also analyzed autophagic markers, such as MAP-LC3 and p62. Microtubule-
associated proteins LC3 (MAP-LC3, herein named LC3) is the major constituent of the 
autophagosome and is widely used as indicators of autophagy, whereas p62 is an 
ubiquitin binding protein whose degradation is directly related to 
autophagosomesclearance. We observed the appearance of LC3-II in the PD samples, 
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indicating that autophagy wasinduced, but, at the same time, we found an increase in 
p62 levels (Fig.8). 
 
 
Fig. 8 Expression of genes involved in autophagy in 3 months PD mice. Western blots of homogenates from quadriceps (A) and 
heart (B) in wt and PD mice. Densitometric analyses are reported below images.* p < 0.05 
 
 
- Effects of ERT and drugs on oxidative stress. 
We next studied the effects of ERT on the levels of ox-stress. First of all, we tested 
whether ERT could rescue oxidative stress in PD patients. The results of TBARS and 
DCFDA assays on homogenates from 3 months GAA WT and KO mice suggest an 
improvement of oxidative stress levels after ERT treatment in all muscles (Fig. 9). 
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Results are different in the liver, in which ERT have no effect on oxidative stress. This 
result is consistent with the minor increase of ox-stress in PD liver compared to other 
organs. 
 
Fig. 9 TBARS and DCFDA assays on homogenates from 3 months GAA WT and KO mice suggest an improving of oxidative stress 
conditions after ERT treatment .* p < 0.05, ** p<0.01 
 
Albeit not statistically significant, the analysis by western blot of phosphorylated ERK 
and p38 proteins in quadricepts and hearts of 3 months WT and KOmice shows the 
same trend of previous experiments (Fig. 10). 
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Fig. 10 Western blot analysis on quadriceps and hearts from 3 months GAA WT, KO andKO + ERT mice suggest an improving of 
oxidative stress conditions after ERT treatment . 
 
We also investigated the effect of known antioxidants on oxidative stress in PD cells. 
Cells were treated with C001 100 µM for 24 hours and analyzed for TBARS and 
DCFDA assays. The results showed a more evident decrease of ROS and lipid 
peroxidation in PD fibroblasts after the treatment with ascorbic acid than in control 
fibroblasts (Fig. 11). 
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Fig. 11 TBARS and DCFDA assays on PD and control fibroblasts. Results show a significant decrease of ROS and lipid 
peroxidation in PD fibroblasts after a 24 hours treatment with C001.* p < 0.01 
 
Gastrocnemii and hearts from WT and GAA KO mice were treated with 3 g/kg with a 
second compound (C002) and ox-stress levels were evaluated by TBARS and DCFDA 
assays. Results showed significant decrease of ox-stress levels in PD mice treated with 
C002, compared to untreated KO mice (Fig. 12). 
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Fig. 12 TBARS and DCFDA assays on gastrocnemius and hearts from WT and GAA KO mice treated with C002 3 mg/kg. Results 
show a significant decrease of ROS and lipid peroxidation in treated PD mice, compared to untreated. * p < 0.01 
 
Furthermore, we investigated about the possible effect of C002 on the efficacy of ERT 
in vitro. We observed an increase rhGAA activity and stability in PD fibroblasts treated 
with C002, compared to untreated, shown by GAA activity assay and western blot 
analysis (Fig. 13). 
 
Fig. 13 A) Percent of GAA activity increasing in PD fibroblasts treated with ERT with and without C002. The anti-oxidant increase 
rhGAA activity in cells, probably improving its stability in cells B). 
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METHODS 
A KO Pompe disease mouse model obtained by insertion of neo into the GAA gene 
exon 6 Raben et al, [1998] was purchased from Charles River Laboratories 
(Wilmington, MA), and is currently maintained at the Cardarelli Hospital's Animal Facility 
(Naples, Italy). Animal studies were performed according to the EU Directive 86/609, 
regarding the protection of animals used for experimental purposes. Every procedure on 
the mice were performed with the aim of ensuring that discomfort, distress, pain, and 
injury would be minimal. Mice were euthanized following anesthesia. Human PD 
fibroblasts (approximately 30 cell lines) are already available at the cell bank of the 
Department of Translational Medical Sciences (DISMET), Section of Pediatrics, 
Federico II University, Naples. 
 
In vivo experiments 
Mice were injected into the retroorbital vein with rhGAA at a dose of 40 mg/kg. The 
animals were killed after 24 hours, the different tissue were harvested, homogenized 
and lysated. Each group of mice was composed of three 12-week-old animals.  
 
Cell Culture 
Fibroblasts from control individuals and from PD patients were obtained from the cell 
repository at the Department of Traslational Medicine, Università degli Studi di Napoli 
Federico II. Fibroblasts were grown in DMEM medium supplemented with fetal bovine 
serum, L-glutamine and antibiotics. Cells were incubated with rhGAA at 50 ng/ul for 6 
hours and with Ascorbic Acid 100 uM for 24 hours. 
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Western Blot 
PD and control fibroblasts and mice tissue protein extracts were obtained by lysing cells 
with RIPA Buffer and protease inhibitors for 3 minutes at 50 oscillations/minute in tissue 
lyser and by five cycles of freeze-thawing. Samples were centrifuged at 13000 rpm for 
30 minutes at 4°C. The supernatant constituted the protein extract. Fibroblast and 
tissues extracts were subjected to sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (7 or 10% acrylamide in different experiments) and proteins were 
transferred to nitrocellulose membrane (Millipore, Billerica, MA). Immunoreactive 
proteins were detected by chemiluminescence (ECL, Amersham, Freiburg, Germany). 
Quantitative analysis of band intensity was performed using ImageJ. 
 
DCFDA assay 
Todetermine the ROS levels within the cytosol, cells were incubated with cell 
permeable, redox-sensitive fluorophore 2',7'-dichlorodihydrofluorescein diacetate (H2-
DCFDA, Sigma-Aldrich) at the concentration of 20 μMfor30 min at 37 °C. Cells were 
then washed with warm PBS supplemented with 1 mM CaCl2, 0.5 mM MgCl2, 30 
mMglucose  (PBS  plus) 2  times,  detached  by  trypsin,  centrifuged  at  1000  g  for  
10  min and  resuspended  in  PBS  plus  at  a  cell  density  of  1x105cells/ml.  After 
diffusion in to the cell, DCFDA is deacetylated by cellular esterases to a non-fluorescent 
compound, which is later oxidized by ROS into 2’, 7’ –dichlorofluorescein (DCF). DCF is 
a highly fluorescent compound which can be detected by fluorescence spectroscopy 
with maximum excitation and emission spectra of 495 nm and 529 nm respectively 
using  a  Perkin-Elmer  LS50  spectrofluorimeter. Emission  spectra  were  acquired  at  
a  scanning  speed  of  300  nm/min,  with  5  slitwidths for excitation and emission. 
ROS production was expressed as percentage of DCF  fluorescence  intensity  of  the  
sample  under  test,  with  respect  to  the  untreated sample.  Three  separate analyses  
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were  carried  outin  triplicate with  each  extract. Control  experiments  were  performed  
by  supplementing  cell  cultures  with  identical volumes of DMSO. 
 
TBARS assay 
The  levels  of  lipid  peroxidation  were  determined  by  using  the  thiobarbituric acid  
(TBA)  reactive  substances  (TBARS)  assay. Since TBA  reacts  with  oxidative 
degradation  products  of  lipids,  and  complexes  absorb  at  532  nm,  this  assay  was 
used  to  determine  lipid  peroxidation  levels. At  the  end  of  the  experiment,  cells  
were detached  by  trypsin,  centrifuged  at  1,000  g  for  10  min  and  5x105 cells  were 
resuspendend  in  ice  cold  PBS  and  mixed  with  0.67%  TBA  and  an  equal  volume 
of 20%  trichloroacetic  acid. Samples  were  then  heated  at  95  °C  for  30  min,  
incubated on ice for 10 min and centrifuged at 3,000g for 5 min, at 4 °C. Samples were 
read at 532 nm. 
 
DTNB assay 
To estimate intracellular GSH levels, the interaction of the sulfhydryl  group of GSH with 
5,5’-dithiobis-2-nitrobenzoic acid (DTNB) was  used.  DTNB produces  a yellow- 
coloured compound, 5-thio-2-nitrobenzoic acid (TNB), whose intensity can be measured 
at 412 nm. Thus, the rate of TNB production is directly proportional to the concentration  
of  GSH  in  the  sample. At  the  end  of  the  experiment,  cells  were detached  by  
trypsin,  centrifuged  at  1000  g  for  10  min  and  resuspendend  in lysis buffer  (300  
mM  NaCl,  0.5%  NP-40  in  100  mM  TrisHCl,  pH7.4)  containing  protease inhibitors. 
After 30 min incubation on ice, lysates were centrifuged at 14,000 g for 30 min  at  4  
°C.  Supernatant  protein  concentration  was  determined  by  Bradford  assay. Then,  
50  μg  of  proteins  were  incubated  with  3  mM  EDTA,  144  μM  DTNB  in  30  mM 
TrisHCl  pH  8.2,  centrifuged  at  14,000g  for  5  min  at  RT and  the absorbance  of  
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the supernatant  was  measured  at  412  nm  using  a  multiplate  reader  (Biorad). The 
intracellular GSH  level determined  using  a  reference  curve  obtain  by GSH as  a 
standard (1-500  μl). GSH  levels  were  expressed  as  percentage  of  TNB  
absorbance of  the  sample  under  test,  with  respect  to  the  untreated  sample.  
Three  separate analyses were carried out with each extract. Control experiments were 
performed by supplementing cell cultures with identical volumes of DMSO. 
 
DCFDA staining 
Gastrocnemii from WT and KO mice were dissected and frozen in isopentane in liquid 
nitrogen. Then they were cut in 10 µm thick tissue sections using a cryostat and were 
mounted onto histological slides. Slides were dried for 30 minutes at room temperature 
and incubated with DCFDA 10 μM in PBS for 15 minutes. After 3 washing step with 
PBS, tissues were analyzed by fluorescence microscopy.  
 
GAA activity assay 
GAA activity was assayed by using the fluorogenic substrate 4-methylumbelliferyl-α-D-
glucopyranoside (Sigma-Aldrich). Briefly, 25 μg of protein were incubated with the 
fluorogenic substrate (2mmol/l) in 0,2 mol/l acetate buffer, pH 4.0, for 60 minutes in 
incubation mixtures of 20 μl. The reaction was stopped by adding 1 ml of glycine-
carbonate buffer, pH 10.7. Fluorescence was read at 365 nm (excitation) and 450 nm 
(emission) on a Turner Biosystem Modulus fluorometer. 
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CONCLUSIONS 
PD pathophysiology and its molecular/cellular mechanisms are not fully understood. It 
has been shown that a failure of productive autophagy in muscle tissue contributes 
strongly to disease pathology in PD patients [1] and would interfere with the correct 
delivery of recombinant enzyme [1, 4]. Improving therapy is an urgent need, so our 
study is focused on study the autophagy impairment in PD and the mechanisms that 
could lead to this alteration. The strong correlation between oxidative stress and 
autophagyhas been fully elucidated. In addition, it has been found that PD mice and 
humans show multiple mitochondrial defects, a profound dysregulation of Ca2+ 
homeostasis and an increase in reactive oxygen species [7]. 
In line with this evidences we investigated about the presence of ox-stress in GAA KO 
mouse muscles and PD patients fibroblasts, and we decided to screen already known 
drugs to improve the oxidative status of cells and evaluate their effects on disease 
pathology. Our data confirmed increasing ox-stress in PD mice tissue (in particular, in 
muscle tissues, as expected) and in patients’ fibroblasts, compared to controls, by 
TBARS, DCFDA and DTNB assay. Western blot analysis of ox-stress markers on mice 
tissue and patients’ fibroblasts also confirmed the same evidence.  
A very interesting data was the positive effect of ERT on ox-stress in muscle tissue from 
PD mice observed by biochemical assays and western blot analysis, even if the reason 
of this effect is not completely clear. Furthermore, when we have treated KO mice and 
PD fibroblasts with antioxidants, we observed a significant improvement of rhGAA 
activity. This data open the way to other answer about the link between autophagy 
impairment and oxidative stress. Our next step is understanding the molecular 
mechanisms underlying this connection and how we can modulate autophagy and ox-
stress pathways as new therapeutic target. Moreover, the use of drugs already on the 
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market could make easier to start new therapeutic approaches in patients. Therefore, 
the connection between autophagy and ox-stress can be the key to better understand 
PD pathophysiology and to address a novel therapeutic approach.  
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microRNA as biomarkers in Pompe Disease 
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INTRODUCTION 
Assessing patient conditions and response to ERT is a critical issue in the management 
of this disorder. A major challenge, in this respect, is the need for reliable, measurable 
and objective markers of disease that are not influenced by inter and intra-investigator 
variance. While objective clinical measures for evaluating cardiac manifestations are 
available, the degree of muscle involvement remains difficult to assess. Currently, 
clinical tests (muscle strength, muscle function, patient-reported outcomes) are in 
common use to this purpose [1]. Although several of these tests have been specifically 
validated for PD [2, 3], some of them appear to be specific for subsets of patients, 
require specific medical skills and collaboration of patients. Key factors in the evaluation 
of these tests are their clinical relevance and the minimal clinically important difference, 
that for some of these tests needs to be further established [1]. Biochemical or imaging-
based tests include the evaluation of the glucose tetrasaccharide (GLC4) [4] in plasma 
and urine, muscle ultrasound [5], muscle NMR [6]. Also in these cases, however, the 
clinical relevance of the tests needs further assessment.  
The availability of reliable tests appears even more important for the development of 
guidelines for patient monitoring, for ERT inclusion and exclusion criteria that are 
currently being defined in many countries [such as UK, and other European countries; 
see EPoC criteria]. A set of reliable clinical and biochemical tests may also prove to be 
useful in optimizing ERT, and may in principle translate into economical benefits. They 
may also be precious tools in evaluating the efficacy of novel treatments or treatment 
protocols in comparison with existing therapies. 
In addition disease markers that provide information on PD pathophysiology may allow 
for identification of new therapeutic targets and, possibly, for development of novel 
therapeutic strategies. 
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We explored the possibility to exploit microRNAs (miRNAs) as markers of disease in 
PD. miRNAs are a small non-coding RNAs that regulate gene expression by targeting 
messenger RNAs. miRNAs are able to concurrently target multiple effectors of 
pathways in the context of a network, thereby finely regulating multiple cellular functions 
involved in disease development and progression [7,8, 9]. 
In several other disease conditions, including muscular dystrophies [10] miRNA profiles 
have provided a read-out of altered pathways in response to disease [11], and have 
indicated potential targets of therapeutic intervention. In this respect, miRNAs have a 
great potential as diagnostic, prognostic and predictive disease biomarkers. Obtaining 
indirect read-outs of pathological processes is particularly important for certain 
disorders, such as PD, in which direct access to the affected tissue for molecular 
analyses would require invasive procedures (muscle biopsy).  
In this study we analyzed the expression of miRNAs by a methodology based on Next-
Generation Sequencing (NGS) and bioinformatic analysis in the PD murine model 
(muscle and heart), and in patients’ plasma, in order to provide an additional measure to 
assess patients clinical conditions and response to treatments.  
  
RESULTS 
- The PD mouse model shows differential expression of miRNAs in 
gastrocnemius and heart. 
miRNAs expression profiles were analyzed by NGS in the mouse model of PD in 
comparison to wild-type animals. The analysis was performed in two tissues that are 
particularly relevant for the disease, heart and gastrocnemius, from PD mice and age-
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matched wild-type mice. The tissues were collected at different time-points (3 and 9 
months) that reflect different stages of disease progression and severity (Fig. 1).  
 
Fig. 1 Experiment plan of NGS analysis in the mouse model of PD in comparison to wild-type animals. 
 
After sample collection and small-RNA sequencing, a bioinformatic analysis was 
performed in order to assess reliability and statistical relevance of data. The threshold 
value for significance used to define up-regulation or down-regulation of miRNAs was a 
False Discovery Rate (FDR) < 0.05. The NGS analysis generated a list of differentially 
expressed miRNAs (DE-miRNA) in the tissues examined. We identified 198 miRNAs 
differentially expressed with statistical significance in gastrocnemius (Fig. 2A, left). Fifty-
five miRNAs were differentially expressed at 3 months, 58 at 9 months, 85 were 
differentially expressed at both ages. We also found 66 DE-miRNAs in heart (Fig. 2A, 
right): 17 miRNAs were differentially expressed at 3 months and 44 at 9 months; 5 
miRNAs were differentially expressed at both ages in heart. 
DE-miRNAs were either up-regulated or down-regulated. In gastrocnemius 98 miRNAs 
were down-regulated and 100 up-regulated, while in heart 31 miRNAs were down-
regulated and 35 were up-regulated. Fig. 2B and C show the heatmaps of each heart- 
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and muscle-specific DE-miRNA identified by NGS. The colors indicate up (red) or down 
(green) regulation of each DE-miRNA; the brilliance of colors is proportional to the 
degree of alteration. We also analyzed plasma from PD mice, but we failed to identify 
DE-miRNAs. 
 
 
Fig. 2 miRNAs expression profiles analyzed by NGS in the mouse model of PD in comparison to wild-type animals. 
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Further analysis was made in order to acquire more information about DE-miRNAs and 
in order to select DE-miRNAs that were functionally involved in relevant processes for 
PD. To this aim target genes were predicted using TargetScan and miRDB. Gene 
Ontology and KEGG pathways analysis were applied to their target pool. As result of 
KEGG frequencies we found the genes that are predicted to be most frequently targeted 
by the DE-miRNAs. The most frequent target genes (that is genes that are predicted 
target at least of 25 DE-miRNAs) are shown in Fig. 3A. Among the most frequently 
targeted genes, some are potentially interesting for PD pathophysiology, while for 
others the possible link is less obvious. 
The predicted target genes of DE-miRNAs are involved in different pathways, including 
cancer, insulin signaling, diabetes mellitus, and others (Fig. 3B). Interestingly, some 
other pathways are potentially relevant for PD, including mTOR signaling pathway, 
endocytosis, ubiquitin-mediated proteolysis, calcium signaling.  This finding was further 
supported by the analysis of literature data, indicating that some DE-miRNAs are 
already known to be implicated in myogenesis, autophagy, cardiac hypertrophy, muscle 
atrophy, fibrosis.  
For example, miR-1 and miR-133, which are co-transcribed, are directly involved in 
differentiation and proliferation of skeletal muscle during development [12]. The 
expression of both miR-1 and miR-133 was enriched in striated muscle, including both 
cardiac and skeletal muscles. In our analysis we found both these miRNAs down-
regulated (miR-1 in gastrocnemius, miR-133 in heart and in gastrocnemius). We found 
the same scenario for others muscular miRNAs; miR-486 has been shown to be 
upregulated during myogenesis [13], while is down-regulated in PD mouse 
gastrocnemius; miR-31 and miR-221 have been reported as reduced in myogenesis 
[14, 15], but in our PD model they were both up-regulated. 
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A few selected DE-miRNAs and their target genes are shown in Fig. 3C. In addition, we 
found some DE-miRNAs that are implicated in other pathways, such as oxidative stress 
and inflammation, that have only occasionally been associated with PD, but are of 
potential interest for the disease pathophysiology.  
Some DE-miRNAs are involved in more than one of these pathways, thus providing a 
picture of the complexity of PD pathophysiology, and of the intricate interplay between 
secondary cellular events triggered in response to glycogen storage. 
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Fig. 3 PD genes that are predicted to be most frequently targeted by the DE-miRNAs and relevant processes for PD in which DE-
miRNAs were functionally involved.  
 
In recent years the role of specific genes in muscle myogenesis, regeneration and 
atrophy has been widely studied, as well as their regulation by miRNAs [16]. We looked 
at the expression levels of 3 genes that are relevant for muscle (FOXO-1, Pten, Pax7) 
and 1 gene involved in autophagy, a pathway that is typically dysregulated in PD 
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(Beclin1) (Fig. 4). These genes are known to be regulated by miRNAs that were found 
to be down-regulated in mice tissues. The analysis was performed by qRT-PCR in mice 
gastrocnemius. 
The Pax family, mainly represented by Pax3 and Pax7, are skeletal muscle progenitor 
cells markers and critical upstream factors involved in the myogenesis. Pax7 is 
essential for the specification of skeletal muscle satellite cells, which are skeletal muscle 
stem cells, as well as for the commitment of the myogenic precursor lineage [17]. 
FOXO-1 is an important factor in atrophy activation [18]. Pten an essential regulator of 
SRF-dependent transcription to control smooth muscle differentiation and involved in 
AKT signaling pathway [19]. 
Pax7, Foxo1 and Pten are all validated target genes of miR-486. MiR-486 promotes 
myogenesis and is downregulated in PD mouse gastrocnemius. Beclin1 plays an 
important role in the autophagic process and is one of the target genes of DE-miRNA 
miR-30a. All these genes are also target of others DE-miRNAs and their function could 
be influenced by different factors. 
All genes resulted to be up-regulated in gastrocnemius, consistent with the down-
regulation of the relevant DE-miRNAs. 
 
Fig. 4 Expression levels of FOXO-1, Pten, Pax7 and Beclin 1 analyzed by qRT-PCR in mice gastrocnemius. 
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- PD patients show differential expression of circulating miRNAs. 
We then looked at plasma samples from patients affected by PD. Plasma samples from 
40 patients, were available at the six clinical centers involved in this study (Università 
degli Studi di Napoli Federico II, Napoli; Università degli Studi di Messina; Università 
degli studi di Torino; Ospedale pediatrico Bambin Gesù, Roma; Azienda Ospedaliero 
Univesitaria Santa Maria della Misericordia di Udine; Erasmus MC: Universitair Medisch 
Centrum Rotterdam). Eight of the patients were affected by infantile-onset PD (IOPD), 
32 by late-onset PD (LOPD).  
Six plasma samples of them were selected for NGS analysis, with the same approach 
used in mice tissues. The patients to be analyzed were selected based on their 
phenotype, current clinical condition and age, in order have homogeneous groups 
representative of both PD patients categories, IOPD and LOPD. The results obtained in 
IOPD patients were compared with those obtained in six controls (3 infants, 3 age-
matched adults, see above).  
We found 55 miRNAs that were significant dysregulated in PD samples with respect to 
controls (28 down-regulated and 27 up-regulated) (Fig. 5A). 
A comparison between the results obtained in mice and those obtained in patients 
plasma showed that 19 miRNAs were differentially expressed both in tissues from the 
PD mouse and in patients plasma. 15 miRNAs were differentially expressed in mouse 
gastrocnemius and plasma, 3 in heart and plasma, one was differentially expressed in 
all samples examined (Fig. 5B).  
Interestingly mir-29c was found to be altered both in tissues of animal model and in 
plasma of PD patients. This miRNA is involved in different relevant process as cancer, 
Alzheimer's disease, cardiomyopathies. miR-29c showed a distinct signature in aortic 
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stenosis, hypertrophic non-obstructive and obstructive cardiomyopathies and thus could 
be developed into a clinically useful biomarker [20].  
MiR-133 has been already proposed (together with other miRNAs) as new and valuable 
biomarkers for the diagnosis of Duchenne muscular distrophy [10] and possibly for 
monitoring the outcomes of therapeutic interventions in humans. In our analysis miR-
133 was dysregulated in plasma from PD patients and in mice gastrocnemius. 
 
 
Fig. 5 NGS analysis of plasma samples from patients affected by PD 
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Fig. 6 shows the results of selected miRNAs that were significant dysregulated in PD 
samples with respect to controls and that are involved in pathway such as autophagy, 
inflammation, muscle regeneration and atrophy. miR-133, -134 and -136 resulted to be 
up-regulated in PD samples, instead of miR-155 and miR-142 that resulted down-
regulated in PD patients. All these miRNAs were dysregulated with high statistical 
significance (0,002 ≤ p ≤ 0,01). For some of them minor overlap between PD  and 
control plasma was detectable. When we considered mi-RNA 155/136 ratio, the 
differences in expression levels between PD and controls became even more significant 
(we used a logarithmic scale). 
We then looked for a pattern of miRNA expression that may rapresent a “signature” of 
PD and a tool to monitor disease progression and the effects of therapies. 
 
Fig. 6Plasma level of some of miRNAs in PD samples with respect to controls  
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METHODS 
A KO Pompe disease mouse model obtained by insertion of neo into the GAA gene 
exon 6 Raben et al, [1998] was purchased from Charles River Laboratories 
(Wilmington, MA), and is currently maintained at the Cardarelli Hospital's Animal Facility 
(Naples, Italy).Animal studies were performed according to the EU Directive 86/609, 
regarding the protection of animals used for experimental purposes. Every procedure on 
the mice were performed with the aim of ensuring that discomfort, distress, pain, and 
injury would be minimal. Mice were euthanized following ketamine xylazine anesthesia. 
Human PD fibroblasts (approximately 30 cell lines) and myoblasts (5 cell lines) are 
already available at the cell bank of the Department of Translational Medical Sciences 
(DISMET), Section of Pediatrics,Federico II University, Naples. Plasma samples were 
collected from 40 PD patients in 7 collaborating centers (DISMET and Department of 
Neurosciences, Federico II University in Naples, University of Messina, Bambino Gesù 
Hospital in Rome, Centre for Rare Disease,  Udine, at Department of Neurosciences, 
University of Turin and at Center for Lysosomal and Metabolic Diseases and at 
Department of Pediatrics, Erasmus University Medical Center, Rotterdam, The 
Netherlands). Plasma was obtained according to standard procedures during periodic 
follow-up admissions to the respective Hospital. Five ml of peripheral blood was 
collected in EDTA and immediately processed, or stored at -80°C. Samples from age-
matched controls were analyzed for comparison. 
Nine muscle biopsy samples are already available at DISMET (kindly provided by Prof. 
Antonio Toscano, Dept. of Neurology, University of Messina, and by Prof. Lucio 
Santoro, Dept. of Neurosciences, Federico II University, Naples). The samples have 
been obtained for diagnostic purposes and patients have consented to their storage and 
use for research. 
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Total RNA extraction preserving miRNA fraction. 
The methodology for extraction and analysis is already established in our laboratories.  
Tissue samples were immediately submerged in RNA Stabilization Reagent (RNA later; 
QIAGEN), to stabilize RNA and preserve the gene expression profile, and frozen. Total 
RNA, including small RNAs, was extracted using the miRNeasy Kit (Qiagen) following 
the manufacturer′s instructions. RNA was quantified using a NanoDrop ND-8000 
spectrophotometer (NanoDrop Technologies) and the integrity was evaluated using an 
RNA 6000 Nano chip on a Bioanalyzer (Agilent Technologies). Only samples with an 
RNA integrity number (RIN)>8.0 were used for library preparation.  
 
Small RNA-seq analysis in tissues 
Small RNA libraries were constructed using a Truseq small RNA sample preparation kit 
(Illumina) following the manufacturer′s protocol. Using multiplexing, we combined up to 
12 samples into a single lane in order to obtain sufficient coverage. Equal volumes of 
the samples that constituted each library were pooled together immediately prior to gel 
purification and the 147-157 bp products from the pooled indexes were purified from a 
6% polyacrylamide gel (Invitrogen). Libraries have been quality-checked using a DNA 
1000 chip on a Bioanalyzer (Agilent Technologies) and quantified using the Qubit® 2.0 
Fluorometer (Invitrogen).  
 
Small RNA-seq analysis in plasma 
For the analysis of circulating miRNA, we collected plasma from PD mice and age-
matched wild-type mice by centrifugation of blood in serological tubes. For the 
preparation of plasma, EDTA was used as anticoagulant. Every effort was made to limit 
pre-analytical variation that could affect miRNA quantification. For instance, particular 
attention was given to prevent hemolysis. We monitored the levels of the granulocyte-
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specific miR-223 to assess the extent of hemolysis in the collected samples. All 
downstream processing of plasma samples from PD and control sets were conducted 
simultaneously to minimize batch effect. Prior to RNA extraction, a C. elegans-specific 
synthetic exogenous miRNA (ce-miR-39) was spiked in the samples as control for the 
extraction efficiency. RNA was isolated using the miRNeasy Kit (Qiagen) and RT-PCR 
was performed using miScript System (Qiagen). RNA recovery was assessed by 
comparing the Ct values (obtained with the assay targeting the synthetic miRNA) with a 
standard curve of the synthetic miRNA generated independently of the RNA purification 
procedure. After the assessment of RNA recovery, equal amounts based on starting 
described for tissue samples. 
The sequencing was carried out by the NGS Core Facility at TIGEM, Naples. Cluster 
generation was performed on a Flow Cell v3 (TruSeq SR Cluster Kit v3; Illumina) using 
cBOT and sequencing was performed on the Illumina HiSeq1000 platform, according to 
the manufacturer’s protocol. Each library was loaded at a concentration of 10 pM, which 
we had previously established as optimal.  
 
Bioinformatics Analysis 
To identify differentially expressed miRNAs (DE-miRNAs) across samples, the raw data 
were analyzed with the support of the Bioinformatics and Statistics Core Facility, 
TIGEM, Naples. Briefly, the reads were trimmed to remove adapter sequences and low 
quality ends, and reads mapping to contaminating sequences (e.g. ribosomal RNA, 
phIX control) were filtered-out. The filtered reads were aligned in parallel both to the 
mouse genome (mm10) and to mouse mature miRNAs (miRBase Release 20) using the 
CASAVA software (Illumina). The number of reads for each miRNA was normalised 
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using Trimmed Mean of MS (TMM). The comparative analysis of miRNA levels across 
samples was performed with edgeR, a statistical package based on generalized linear 
models, suitable for multifactorial experiments. 
The potential role, the target genes, and the pathways in which DE-miRNA identified by 
NGS were involved, were studied by bioinformatics tools (Gene Ontology, KEGG 
frequencies) and literature-based analysis (PubMed).  
Quantitative Real-time Reverse-transcription Polymerase Chain Reaction (qRT-PCR) of 
miRNA and of specific target genes. 
Expression of mature miRNAs were assayed using Taqman MicroRNA Assay (Applied 
Biosystems) specific for each miRNA selected for validation. qRT-PCR was performed 
by using an Applied Biosystems 7900 Real-time PCR System and a TaqMan Universal 
PCR Master Mix. All the primers for selected miRNAs were obtained from the TaqMan 
miRNA Assays. Samples were run in triplicate and small nuclear U6 snRNA and miR-16 
(Applied Biosystems) were used as internal controls.  
Differences in miRNAs expression, expressed as fold-changes, were calculated using 
the 2-DDCt method. To validate the target genes expression data, qRT-PCR was 
performed for selected target genes of some miRNAs. GAPDH, was used as 
endogenous reference transcript. The levels of selected target genes were measured by 
qRT-PCR using the LightCycler 480 (Roche) and specific forward and reverse primers 
for each target gene. The PCRs with cDNA were carried out in a total volume of 20 µl, 
using 10 µl LightCycler 480 SYBR Green I Master Mix (Roche) and 400nM specific 
primers under specific conditions that were validated for each of the genes analyzed. All 
the reactions were normalized against murine or human GAPDH. Each sample was 
analyzed in duplicate in two-independent experiments. 
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In vivo experiments on PD mouse model 
PD ko mice received single injection of Myozyme into the retro-orbital vein (doses: 40 
mg/kg; 100 mg/kg). The dose of 40 mg/kg corresponds to the dose used in human 
therapy. Plasma and tissue (heart, gastrocnemius) were collected 24 hrs or 48 hrs after 
the infusion and selected miRNA and mRNAs were analyzed by qRT-PCR as indicated. 
The results were compared with those obtained in untreated animals. For each group 
(treated, untreated, different time points) 5 animals were tested. 
 
Plasma was obtained according to standard procedures during periodic follow-up 
admissions to the respective Hospitals. Peripheral blood was collected in EDTA and 
immediately processed, or stored at -80°C. Samples from age-matched controls were 
analyzed for comparison. 
RNA was extracted (as described) and analyzed by qRT-PCR as indicated above.  
 
Patients 
Forty PD patients were recruited for the study. The patients were followed at six Italian 
centers and one Dutch center (Department of TranslationalMedicine, Federico II 
University of Naples, Department of Neurosciences, Federico II University of Naples, 
University of Messina, Bambino Gesù Hospital of Rome, Centre for Rare Disease of 
Udine, Department of Neurosciences, University of Turin and Center for Lysosomal and 
Metabolic Diseases and Department of Pediatrics, Erasmus University Medical Center, 
Rotterdam, The Netherlands). All these Institutions are referral centers for the 
diagnosis, care and follow-up of inborn errors of metabolism. In all patients, the clinical 
and enzymatic diagnosis was confirmed by the molecular analysis of the GAA gene. 
Each patient ID is composed by initials of the city center + progressive number. 
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Plasma was obtained according to standard procedures during periodic follow-up 
admissions to the respective Hospital. Patients (or their legal guardians) signed an 
informed consent agreeing that samples obtained would be stored and used for the 
study purposes and for possible future research purposes. 
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CONCLUSIONS 
The availability of objective, reliable and reproducible tests is important to assess 
disease progression and to monitor efficacy of therapies in PD patients. Currently, like 
in many other myopathies, most of the indicators of PD rely on clinical tests or patient-
reported outcome measures, with only a few based on biochemical assays. 
We have evaluated miRNAs as potential biomarkers for PD. We initially performed our 
analysis in the murine model of the disease in order to start with a homogenous sample, 
with a common genetic background and uniform disease progression. PD patients are 
highly heterogeneous with respect to phenotype, disease course, response to ERT, and 
appeared to be not appropriate for the initial screening of DE-miRNAs.  In addition, the 
use of the murine model of the disease allowed for analysis of tissues, that in patients 
would require invasive procedures. We studied miRNAs profiles in tissues from PD mice 
at two stages of disease progression, 3 and 9 months. We used an approach based on 
next generation sequencing (NGS), a powerful and innovative tool that allows large-
scale quantitative analysis of genes and nucleotide sequences. The NGS-by-synthesis 
approach allows for detection of even small differences among samples, and enables 
the identification of non-annotated miRNAs. In addition, the NGS-by-synthesis approach 
allows for detection of even small differences among samples, and enables the 
identification of non-annotated miRNAs. 
We identified 198 miRNA that were differentially expressed with statistical significance 
(FDR< 0.05) in muscle (gastrocnemius), and 66 in heart. In total, 72 miRNAs were 
differentially expressed at 3 months, 102 at 9 months, 90 were differentially expressed 
at both ages.  
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Interestingly, some of these miRNAs are already known to modulate the expression of 
genes involved in pathways such as autophagy, muscle regeneration, inflammation that 
may be relevant for PD pathophysiology. This supports the value of our analysis. 
In patients we performed NGS analysis, with the same approach used in mice tissues. 
Expression levels of all 55 DE-miRNAs found by NGS analysis in control and PD 
plasma samples will be further evaluated. 
This research has the potential to generate reliable tools for PD that can be used in 
clinics to monitor disease progression and ERT efficacy, to provide information on the 
disease pathophysiology, and to help optimize therapeutic interventions. 
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GENERAL CONCLUSION 
PD phenotype, biochemical and molecular basis have been fully characterized. A 
treatment, ERT, has been developed and approved in 2006, with remarkable success in 
prolonging patients survival and improving motor and respiratory functions. 
Nevertheless, many aspects of PD pathophysiology remain elusive. In addition ERT has 
limited efficacy, indeed not all patients respond equally well to treatment and skeletal 
muscle is more refractory to treatment than other tissues; moreover the evaluation of its 
efficacy is difficult. 
Current issues that deserve future investigation in PD are: 
- Need for full understanding of the disease pathophysiology 
- Identification of additional therapeutic targets and strategies to improve the efficacy 
of ERT 
- Identification of novel markers of disease progression and efficacy of therapies. 
The scope of the present work was to address these issues.We have investigated: 
a) GAA interactions 
b) Ox-stress in PD 
c) miRNAs as biomarkers in PD 
a) Interaction of GAA with GSN. The role of this interaction is not clear. Perhaps it is 
involved in the (early) trafficking of GAA or of both proteins. However, this indicates that 
there is much to learn about the pathophysiology of PD. A complete understanding of 
these processes may open the way to the discovery of new therapeutic targets. 
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b) Ox-stress in PD. The derangement of secondary pathways is emerging as an 
important factor in many LSDs, including PD. In PD autophagy is known to be altered 
and a close interaction between autophagy and ox-stress has been shown. In addition, 
it has been found that PD mice and humans show multiple mitochondrial defects, a 
profound dysregulation of Ca2+ homeostasis and an increase in reactive oxygen 
species. 
We have provided several lines of evidence supporting the presence of increased ox-
stress in PD, both in vitro (fibros from patients) and in vivo, in the PD mouse model. Ox-
stress may become a novel therapeutic target and can be decreased by using known 
drugs. It may impact on the efficacy of therapies, such as ERT; indeed, when we have 
treated KO mice and PD fibroblasts with C002, we observed a significant improvement 
of rhGAA activity. 
We have tested few antioxidant drugs derived from literature analysis but we may test 
more drugs.Therefore experiments in vitro may be a useful tool, that may be 
pharmacologically manipulated and then tested in vivo, in mouse model, for the 
functional effects. 
c) miRNAs as biomarkers in PD. Assessing patient conditions and response to ERT is 
a critical issue in the management of PD. A major challenge, in this respect, is the need 
for reliable, measurable and objective markers of disease. In our work we found: 
- 198 miRNAs differentially expressed with statistical significance in gastrocnemius and 
66 DE-miRNAs in heart in mouse model 
- 55 miRNAs differentially expressed in patients’ plasma. 
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It was an expected result to find more DE-miRNAs in tissue and less in plasma. De-
miRNAs found in plasma are involved in processes and pathways that are known to be 
relevant for PD. 
Obviously, it is necessary to perform more studies on large cohorts of patients to 
establish possible correlations between miRNAs and ERT or disease progression. 
 
